Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Temferon |
Trade Name | |
Synonyms | Autologous CD34+-enriched HSPCs transduced with VSV-G encoding IFN-a2 |
Drug Descriptions |
Temferon comprises autologous hematopoietic stem progenitor cells engineered with a lentiviral vector to express IFN-alpha2 in the tumor microenvironment, which may induce apoptosis in tumor cells and activate antitumor immune response (Blood (2021) 138 (Supplement 1): 2844, NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C172105 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cabozantinib + Temferon | Cabozantinib Temferon | 0 | 1 |
Pembrolizumab + Temferon | Pembrolizumab Temferon | 0 | 1 |
Temferon | Temferon | 0 | 1 |